Lincoln Pharma has reported its best-ever results in a financial year with the highest revenue, EBITDA and net profit for FY ended March 2022. The company has recommended a dividend of 15 per cent, Rs 1.50 per share on the face value of Rs 10 per share for the FY 2021-22, a statement from the company said.
The company reported net profit of Rs 69.36 crores for FY22 as against net profit of Rs 62.25 crores in the corresponding period last year, growth of 11.42 per cent. The net revenue from operations for FY22 was reported at Rs 472.08 crores, higher by 11.63 per cent over previous fiscal’s same period revenue of Rs 422.91 crores. The company also reported EBITDA of Rs 105.47 crores in FY22, rise of 13.67 per cent as compared to EBITDA of Rs 92.78 crores in FY21. EPS for FY22 was reported at Rs 34.63 per share, according to the statement.
CRISIL Ratings has upgraded its ratings on the bank facilities of Lincoln Pharma to ‘CRISIL A/Stable/CRISIL A1’ from CRISIL A-/Positive/CRISIL A2+.
CRISIL report stated, “The rating upgrade reflects the Lincoln group’s improved business profile and the continued consolidation in the financial risk profile. Over the medium term, the group is expected to maintain its growth trajectory and healthy margin. This shall be supported by addition of Cephalosporin which has potential to add around 30 per cent to the topline over next three fiscals. Further, the group’s European market foray shall provide additional fillip to the business profile.”